Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AGV05
- Development stage
- Preclinical
- Lead developer
- AGV Discovery
- Modality
- Small Molecules
01
Overview
AGV05 is an early-stage small molecule oncology candidate being developed by AGV Discovery. Currently in the hit-to-lead phase of preclinical development, AGV05 was identified using the company's Fragment-Based Drug Design (FBDD) platform. AGV Discovery focuses on developing therapies for advanced cancers, with a particular research emphasis on cancer stem cells and circulating tumor cells, often in the context of advanced colorectal cancers. While the specific molecular target for AGV05 has not been publicly disclosed, it represents one of the core programs in the company's internal pipeline aimed at addressing unmet needs in oncology.
Beyond the preview
Go deeper on AGV05.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AGV05.